Merck & Co. and Ridgeback Biotherapeutics have reported more complete data from a study of the antiviral drug molnupiravir as a treatment for COVID-19. An analysis of information from all 1,433 study participants showed that molnupiravir reduced the risk of hospitalization or death by 30%, from 9.7% to 6.8%. Previous interim data showed a 48% risk reduction from 14.1% to 7.3%.